Compugen (NASDAQ:CGEN) Issues Earnings Results, Misses Expectations By $0.14 EPS

Compugen (NASDAQ:CGEN) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14), Zacks reports. Compugen had a return on equity of 2.62% and a net margin of 2.67%.

Compugen Price Performance

Shares of Compugen stock opened at $1.81 on Tuesday. The firm has a 50 day simple moving average of $2.04 and a 200 day simple moving average of $1.84. Compugen has a fifty-two week low of $1.35 and a fifty-two week high of $3.03. The firm has a market cap of $161.52 million, a P/E ratio of 90.50 and a beta of 2.65.

Analysts Set New Price Targets

Separately, Oppenheimer assumed coverage on Compugen in a research note on Monday, January 13th. They issued an “outperform” rating and a $4.00 target price for the company.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.